Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2011-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2010.01325.xPMID 21114604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

  2010cited by this paper
• weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience

  2010cited by this paper
• Hypoglycemia, Diabetes, and Cardiovascular Events

  2010cited by this paper
• Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population

  2010cited by this paper
• Avoiding hypoglycaemia while achieving good glycaemic control in type 2 diabetes through optimal use of oral agent therapy

  2010cited by this paper
• Role of vildagliptin in managing type 2 diabetes mellitus in the elderly

  2010cited by this paper
• An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials

  2010influential reference
• Proinflammatory and Prothrombotic Effects of Hypoglycemia

  2010cited by this paper
• Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment‐naive patients with type 2 diabetes mellitus

  2009cited by this paper
• Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin

  2009cited by this paper
• Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies

  2009cited by this paper
• Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24‐week, double‐blind, randomized trial

  2009cited by this paper
• Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus

  2009influential reference
• Fifty‐two‐week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

  2009cited by this paper
• Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes.

  2009cited by this paper
• Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 Diabetes

  2009cited by this paper
• How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS survey.

  2009cited by this paper
• A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study

  2009cited by this paper
• Diabetes medications and body weight

  2009cited by this paper
• Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes

  2009cited by this paper
• Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial

  2008cited by this paper
• New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly

  2008cited by this paper
• Sustained Efficacy and Reduced Hypoglycemia during One Year of Treatment with Vildagliptin Added to Insulin in Patients with Type 2 Diabetes Mellitus *

  2008cited by this paper
• Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes—the ‘dead in bed’ syndrome revisited

  2008cited by this paper
• Efficacy and tolerability of vildagliptin in drug‐naïve patients with type 2 diabetes and mild hyperglycaemia *

  2008cited by this paper
• Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemia

  2008cited by this paper
• Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet

  2008cited by this paper
• Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study

  2007cited by this paper
• Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP‐4 inhibitors

  2007cited by this paper
• Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes

  2007cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Management of Type 2 Diabetes in Treatment-Naive Elderly Patients

  2007cited by this paper
• Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes

  2007cited by this paper
• Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes

  2007cited by this paper
• Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24‐week, randomized, double‐blind study *

  2007cited by this paper
• Heart failure prevalence, incidence, and mortality in the elderly with diabetes.

  2004cited by this paper
• Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

  2004cited by this paper
• [Management of type 2 diabetes in the elderly].

  2004cited by this paper
• The epidemiology of lower-extremity disease in veterans with diabetes.

  2004cited by this paper
• Hypoglycaemia in Elderly Patients with Diabetes Mellitus

  2004cited by this paper
• Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention.

  2004cited by this paper
• Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance.

  2003cited by this paper
• Aging and insulin secretion.

  2003cited by this paper
• Complications of diabetes in elderly people

  2002cited by this paper
• Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring.

  2002cited by this paper
• Diabetes in elderly adults.

  2001cited by this paper
• Management of Type 2 Diabetes Mellitus in the Elderly

  2001cited by this paper
• Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994

  1998cited by this paper
• Mortality in older people with diabetes mellitus

  1997cited by this paper
• Counterregulatory Hormone Responses to Hypoglycemia in the Elderly Patient with Diabetes

  1994cited by this paper

• Клинические перспективы фиксированной комбинации вилдаглиптина и метформина в управлении сахарным диабетом

  2025cites this paper
• Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective

  2024cites this paper
• Risk Stratification in People with Diabetes for Fasting During Ramadan: Consensus from Arabic Association for the Study of Diabetes and Metabolism

  2023influential citation
• Asian Best Practices for Care of Diabetes in Elderly (ABCDE)

  2022cites this paper
• Tratamiento de la diabetes mellitus tipo 2 en personas de edad avanzada o frágiles. Actualización 2022 del documento de consenso 2018 «Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano»

  2022cites this paper
• Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study

  2022cites this paper
• Which antidiabetic drug indications are recommended for geriatric DM patients?

  2021cites this paper
• A RANDOMIZED, OPEN LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF VILDAGLIPTIN AND METFORMIN COMBINATION VERSUS VILDAGLIPTIN ALONE IN TYPE 2 DIABETES MELLITUS PATIENTS IN A TERTIARY CARE HOSPITAL

  2019cites this paper
• Diabetes Management in Older Adults With Chronic Kidney Disease

  2019cites this paper
• Protective effect of incretin aganist age-related disease.

  2019cites this paper
• Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus

  2019cites this paper
• Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios

  2018cites this paper
• Treatment of type 2 diabetes mellitus in elderly patients.

  2018cites this paper
• Diabète du sujet âgé

  2018cites this paper
• Treatment of type 2 diabetes mellitus in elderly patients

  2018cites this paper
• Diabetes del paciente anciano

  2018cites this paper
• [Use of dipeptidyl peptidase-4 inhibitors in diabetic patients in special situations].

  2018cites this paper
• Tratamiento de la diabetes mellitus tipo 2 en el paciente anciano

  2018cites this paper
• A comparison of the anti-diabetic potential of d-ribose-l-cysteine with insulin, and oral hypoglycaemic agents on pregnant rats

  2018cites this paper
• Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A cross-sectionalcomparative study

  2018cites this paper
• Spécificités du diabète de type 2 chez le sujet âgé

  2017cites this paper
• Metabolic decompensation in older people

  2017cites this paper
• A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes.

  2017cites this paper
• NUEVOS FÁRMACOS EN DIABETES MELLITUS

  2016cites this paper
• A randomized controlled clinical trial of combination therapy for type 2 diabetes by vildagliptin, metformin, and α-glucosidase inhibitor

  2016cites this paper
• Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand

  2016cites this paper
• Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study

  2016cites this paper
• Update on the treatment of type 2 diabetes mellitus.

  2016cites this paper
• [Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors].

  2016cites this paper
• Quelle place pour les nouveaux antidiabétiques dans la prise en charge du diabète du sujet âgé

  2016cites this paper
• Dipeptidyl peptidase‐4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes

  2015cites this paper
• Hot Topics in Primary Care: Management of Opioid-induced Constipation.

  2015cites this paper
• Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey – GALATA study

  2015cites this paper
• Uncertainties around incretin-based therapies: A literature review

  2015cites this paper
• Diabetes mellitus – an overview

  2015cites this paper
• Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.

  2015cites this paper
• Sitagliptin for Elderly Patients Aged 75 Years or Older with Inadequately Controlled Type 2 Diabetes with Common Antidiabetes Treatments

  2015cites this paper
• Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients

  2015cites this paper
• Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial

  2015cites this paper
• Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

  2014cites this paper
• Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study

  2014cites this paper
• Étude HYPOCRAS : comparaison en vie réelle chez des patients âgés diabétiques de type 2 d’un traitement par inhibiteur de la DPP-4 versus autres antidiabétiques oraux en ajout à la metformine

  2014cites this paper
• Chapter 42 - Insulin, other hypoglycemic drugs, and glucagon

  2014cites this paper
• [Liver injury induced by linagliptine and sitagliptine: it' a class effect?].

  2014cites this paper
• Understanding the Molecular Dynamics of Type-2 Diabetes Drug Target DPP-4 and its Interaction with Sitagliptin and Inhibitor Diprotin-A

  2014cites this paper
• Treatment of type 2 diabetes mellitus in the older adult: a review.

  2014cites this paper
• Optimal therapy of type 2 diabetes: a controversial challenge

  2014cites this paper
• [Treatment of older persons with diabetes].

  2014cites this paper
• A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus

  2014cites this paper
• Randomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus

  2014cites this paper
• Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

  2014cites this paper
• Gliptin ist für viele die richtige Antwort

  2014cites this paper
• [Diabetes mellitus type 2 in the elderly. It is essential to know how to personalise the management].

  2014cites this paper
• Observational Study on Dipeptidyl Peptidase-4 Inhibitors: A Real-Life Analysis on 360 Patients from the ASL VCO Territory in Italy

  2014cites this paper
• Glycemic effects of vildagliptin and metformin combination therapy in Indian patients with type 2 diabetes: An observational study (印度2型糖尿病患者使用维格列汀与二甲双胍联合治疗对血糖的影响：一项观察性研究)

  2014cites this paper
• Hepatotoxicidad inducida por linagliptina y sitagliptina: ¿es un efecto de clase?

  2014cites this paper
• Efficacy and safety of dipeptidyl peptidase‐4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta‐analysis

  2014cites this paper
• Diabetische Entgleisung im Alter

  2013cites this paper
• What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?

  2013cites this paper
• Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety

  2013cites this paper
• Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin

  2013cites this paper
• Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin

  2013cites this paper
• Experience with Vildagliptin in Type 2 Diabetic Patients Fasting During Ramadan in France: Insights from the VERDI Study

  2013cites this paper
• The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups

  2013cites this paper
• Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment

  2013cites this paper
• Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment.

  2013cites this paper
• CONFERENCIA DE CONSENSO: TRATAMIENTO DE LA DIABETES TIPO 2 EN EL PACIENTE ANCIANO CONSENSUS STATEMENT: TREATMENT OF TYPE 2 DIABETES IN THE ELDERLY

  2013cites this paper
• Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

  2013cites this paper
• DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes

  2013cites this paper
• DPP-4 inhibitors and hypoglycemia in the patients with type 2 diabetes mellitus

  2013cites this paper
• [Treatment of type 2 diabetes in the elderly].

  2013cites this paper
• Inhibitory DPP-4 u osób starszych – bezpieczeństwo i skuteczność w jednym?

  2013cites this paper
• Effects of Vildagliptin/Metformin Therapy on Patient-Reported Outcomes: Work Productivity, Patient Satisfaction, and Resource Utilization

  2013cites this paper
• Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

  2013cites this paper
• Vildagliptin: a DPP-4 inhibitor for the treatment of Type 2 diabetes

  2012cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin

  2012cites this paper
• Dipeptidyl Peptidase-4 Inhibitors: 3 Years of Experience

  2012cites this paper
• Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin

  2012cites this paper
• Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus

  2012cites this paper
• Management of Type 2 Diabetes Mellitus in Older Adults

  2012cites this paper
• Incretin Therapies in the Management of Patients with Type 2 Diabetes Mellitus and Renal Impairment

  2012cites this paper
• DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

  2012cites this paper
• Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.

  2012cites this paper
• Real-life comparison of DPP4-inhibitors with conventional oral antidiabetics as add-on therapy to metformin in elderly patients with type 2 diabetes: the HYPOCRAS study.

  2012cites this paper
• A review of gliptins in 2011

  2012cites this paper
• Vildagliptin Added to Metformin on β-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients

  2012cites this paper
• Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus

  2012influential citation
• Individualized Treatment of Type 2 Diabetes Mellitus Using Noninsulin Agents: Clinical Considerations for the Primary Care Physician

  2012cites this paper
• Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?

  2012cites this paper
• Non-Insulin Agents for Diabetes

  2012cites this paper
• Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management

  2011cites this paper
• Management of hyperglycemia in geriatric patients with diabetes mellitus: South Asian consensus guidelines

  2011cites this paper
• Diabetes and insulin resistance in older people.

  2011cites this paper
• Management of type 2 diabetes mellitus in the elderly.

  2011cites this paper
• Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

  2011cites this paper
• Pharmacology of Dipeptidyl Peptidase-4 Inhibitors and Differences

  2011cites this paper
• Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

  2011cites this paper
• Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24‐week randomized placebo‐controlled trial

  2011cites this paper
• Incretin Therapies in the Management of Elderly Patients with Type 2 Diabetes Mellitus

  2011cites this paper
• Choosing Targets for Glycaemia, Blood Pressure and Low-Density Lipoprotein Cholesterol in Elderly Individuals with Diabetes Mellitus

  2011cites this paper